Parkinson's disease

Research hypothesis. Possible connections between Parkinson's disease and Alpha-1 Antitrypsin on this page come from early laboratory and biomarker research. They are not established medical fact and are not medical advice. Always work with your neurology team.

What is Parkinson's disease?

Parkinson's disease is a progressive neurological condition that affects movement, often with tremor, stiffness, and slowed motion. Diagnosis and treatment belong with neurology specialists and established clinical guidelines.

Research framing

Mark Egly's patent-pending application includes neurological conditions such as multiple sclerosis and ALS. Parkinson's disease is also a neurological condition with an inflammatory component, and the Foundation includes it within that neurological focus because of early laboratory research on Alpha-1 Antitrypsin and brain inflammation, summarized below. Inclusion signals research interest, not proven cause and effect.

Selected Scientific Anchors

1. Preclinical only (mouse and cell study). In a mouse model of Parkinson's disease (MPTP), the transcription factor RUNX1 switched on the AAT gene (SERPINA1). Raising SERPINA1 or RUNX1 shifted brain immune cells (microglia) toward a less inflammatory state and reduced nerve-cell injury; lowering SERPINA1 blunted that shift. [1]
2. Preclinical only (mouse and cell study). In mice with α-synuclein–driven disease, AAT given into the brain reduced microglial NLRP3 inflammasome–related inflammation through cannabinoid receptor 2 (CB2) signaling and improved some non-motor behaviors. It did not improve motor performance. [2]
3. Human observational (biomarker) study. In spinal fluid from 102 people, a modified form of the SERPINA1 protein differed between Parkinson's patients with dementia and those without dementia or healthy controls. This is a possible risk marker, not evidence about treatment. [3]

How this may relate to Alpha-1

Alpha-1 Antitrypsin (AAT) is best known as an inhibitor of the neutrophil enzymes neutrophil elastase, proteinase 3, and cathepsin G. [C] Separately from that protease inhibition, the laboratory studies above observed effects on inflammatory microglia. These are laboratory observations only; whether this happens in people with Parkinson's is unknown.

As of 15 October 2026, we found no human clinical trials of Alpha-1 Antitrypsin for Parkinson's disease registered on ClinicalTrials.gov.

What you can do

Standard neurology care for Parkinson's disease is unchanged by this research. Continue neurology guided care for Parkinson's disease. The Mark Egly Foundation offers education and community support:

• AATD and neurological conditions
• Alzheimer's disease
• Amyotrophic lateral sclerosis (ALS)
• Multiple sclerosis
• Support research

References

[1] Zhang K, Ding S, Li T, Yuan T, Cai X. SERPINA1 activation by RUNX1 drives microglial M2 polarization and reduces neuronal injury in a Parkinson's disease mouse model. Cytotechnology. 2026;78(1):12 (published online 9 Dec 2025). doi:10.1007/s10616-025-00878-5. PMID 41383367. Evidence level: Preclinical. PubMed · DOI

[2] Feng L, Lo H, Weng W, et al. α1-Antitrypsin attenuates microglial NLR family pyrin domain containing 3 inflammasome activation via cannabinoid receptor 2 signaling to ameliorate α-synucleinopathy-related behavioral deficits. Mol Biomed. 2026;7(1):180. doi:10.1186/s43556-026-00583-5. PMID 42763829. Evidence level: Preclinical. PubMed · DOI

[3] Halbgebauer S, Nagl M, Klafki H, et al. Modified serpinA1 as risk marker for Parkinson's disease dementia: analysis of baseline data. Sci Rep. 2016;6:26145. doi:10.1038/srep26145. PMID 27184740. Evidence level: Human observational. PubMed · DOI

[C] Janciauskiene S, Welte T. Well-known and less well-known functions of alpha-1 antitrypsin. Its role in chronic obstructive pulmonary disease and other disease developments. Ann Am Thorac Soc. 2016;13(Suppl 4):S280-S288. doi:10.1513/AnnalsATS.201507-468KV. PMID 27564662. PubMed · DOI

References checked: 15 October 2026

Research hypothesis. This page is educational only and is not a diagnosis or treatment plan. Alpha-1 Antitrypsin is not an approved treatment for Parkinson's disease. Continue standard care with your neurologist or specialist team.